Day 1: 20 September 2021

10:00 (CET)
Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors

Astero Klampatsa

Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK


Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity

Andreas Pircher

Department of Internal Medicine V (Hematology and Oncology) Medizinische Universität Innsbruck, Innsbruck, Austria

Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden

Jonathan A. Kelber

Department of Biology, California State University Northridge (CSUN), Los Angeles, California

Glucocorticoids and Angiogenesis

Julie Goodwin

Yale School of Medicine, New Haven, CT, USA

Cracking open the undruggable RAS: A Clinical Perspective

David S.Hong

Associate Vice President of Clinical Research, University of Texas M.D. Anderson Cancer Center, Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, USA.

Identification of distinct immune signatures in malignant pleural mesothelioma

Cara Haymaker

Director, Oncology Research and Immuno-monitoring Core (ORION) Director, Translational Molecular Pathology and Immunoprofiling Lab, UT MD Anderson Cancer Center, Houston, TX, US

Development of a novel biodegradable chemo-radioembolic formulation for transarterial treatment of hepatocellular carcinoma (Poster Talk)
Asseel AlregibSchool of Medicine, Taylor’s University, Subang Jaya, Malaysia
Day End

Day 2: 21 September 2021

10:00 (CET)
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Armando Bartolazzi

Department of Pathology, Sant’Andrea University Hospital, Rome, Italy

Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment

Francesca Granucci

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance

Marzia Del Re

Unit of Clinical Pharmacology and Pharmacogenetics, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Combination of integrated genomics with ex vivo microcancer drug screens to individualize brain cancer therapy

Panos Z. Anastasiadis

Cell Biology Program Director, Cell Adhesion and Metastasis Laboratory Mayo Clinic Cancer Center, Jacksonville, FL, USA

Age of combination therapy in the treatment of advanced RCC: can we do it better?

Che-Kai Tsao

Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA

Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib (Poster Talk)
Iris Car

University of Rijeka, Department of Biotechnology, Rijeka, Croatia

Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments | satellite symposium

Pedro Barata, Jorge A. Garcia and Elisabeth Heath

*Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana,USA., *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. and *Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan

Day End

Day 3: 22 September 2021

10:00 (CET)
Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature

Antonio Facchiano

Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy

11:00 (CET)
MET as a druggable target in solid tumors

Qian Xie

Department of BioMedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, US

Molecular Testing and Liquid Biopsy for Ovarian Cancer

Jianyu Rao

UCLA Medical Center, Santa Monica, LA, USA

Flexible samarium-153 radiotherapeutic bandage for radiation therapy of skin cancer

Wong Yin How

School of Medicine, Faculty of Health & Medical Sciences, Taylor’s University, Subang Jaya, Malaysia

Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function

Michael Levin

Tufts University, Medford, USA

Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer (Poster Talk)
Jing LiUniversitat Autònoma de Barcelona, Barcelona, Spain

Day 4: 23 September 2021

10:00 (CET)
Potential prostate cancer targeting strategies revealed by integrative proteogenomics

Leena Latonen

School of Medicine, Institute of Biomedicine, University of Eastern Finland Kuopio, Finland

Two retrospective studies on gender differences: chemotherapy toxicities in patients affected by colorectal and pancreatic cancers

Silvia De Francia

Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy

Mesenchymal stem/stromal cells and the tumor tissue microenvironment

Yufang Shi

Soochow University Institutes for Translational Medicine & Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China

Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma

Cristina M. Failla

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

Targeting glycosaminoglycans in solid tumors

Mads Daugaard

Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre Department of Urologic Sciences, University of British Columbia, Vancouver, Canada

Designing a Multi-Epitope Vaccine Against Cancer-Testis Antigens in Non-Small Cell Lung Cancer: an In Silico Approach (Poster Talk)
Leana Rich M. HerreraPolytechnic University of the Philippines, Philippines
Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible? | satellite symposium

Shilpa Gupta, Vadim Koshkin and Jorge A. Garcia

*Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, *Division of Hematology and Oncology, University of California San Francisco and *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA

Day End

Day 5: 24 September, 2021

10:00 (CET)

Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response

Bruna Corradetti

Houston Methodist Research Institute, Houston, USA & School of Medicine at Swansea University, Wales, UK

A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients

Moonsoo M. Jin

Director, Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, USA

Imaging of tumor acidosis for monitoring response to novel anticancer therapies

Dario Longo

Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR) Torino, Italy

Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data

Y-h. Taguchi

Department of Physics, Chuo University, Tokyo, Japan

The Third Dimension in Prostate Cancer

Francisco La Rosa

University of Colorado, AMC Department of Pathology, Aurora, CO, US

Solid Tumors: Immuno-Oncology

Disis, Mary L. (Nora)

Director, Cancer Vaccine Institute, University of Washington (UW) Director, Institute of Translational Health Sciences UW, Seattle, WA, USA

Day End

Day 6: 25 September, 2021

10:00 (CET)
The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells

Sanja Aveic

Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy RWTH Aachen University Hospital, Dental Materials and Biomaterials Research, Aachen, Germany

The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology

Pier Giorgio Natali

Ex. Scientific Director, Regina Elena Institute (IRE), Rome, Italy

Prognostic factors on her2-positive metastatic breast cancer patients treated with trastuzumab emtansine – real-world study (Poster Talk)
Maria João SousaOncology Institute of Coimbra, Coimbra, Portugal
Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution

Eugene V Koonin

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA

Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | satellite symposium

Ehab Atallah, Giuseppe Saglio and Kendra Sweet

*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, *Division of Internal Medicine and Haematology, University of Turin, Turin, Italy and *Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

Day End

Day 7: 26 September, 2021

10:00 (CET)

The Role of p63 in the Female Germline Fidelity and Related Cancers

Gerry Melino

Faculty of Medicine, University of Rome – Tor Vergata, Rome, Italy


The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies

Licia Iacoviello

IRCCS Neuromed, Pozzilli & University of Insubria Varese, Italy

Apocrine breast carcinoma from biomarkers to therapy

Zoran Gatalica

Director of Anatomic Pathology, University of Oklahoma Health Sciences Center, Oklahoma, USA.

The Evolution of Precision Medicine- Entering the Era of Multi-omics

John L. Marshall

Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Washington DC, USA


A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma (Poster Talk)

Ye-Lin Liang

 Sun Yat-sen University Cancer center, Guangzhou, China


Associating Transcriptomics Data with Inflammatory Markers to Understand Tumour Microenvironment in Hepatocellular Carcinoma (Poster Talk)

Basak Bahcivanci

College of Medical & Dental Sciences, University of Birmingham, Birmingham , UK

Congress End

Agenda is being updated regularly